70 results
How does Paradise renal denervation fit into hypertension treatment management?
20 May 2021 – From EuroPCR 2021
Watch this session presented by Felix Mahfoud, Philipp Lurz, Konstantinos Tsioufis and Joachim Weil in order to understand the ultrasound-based renal denervation procedure and summary of the latest clinical data, to review consensus statements and guidelines for the renal denervation therapy today, and to hear expert perspectives on how to establish...
Redefining hypertension management with renal denervation
19 May 2021 – From EuroPCR 2021
Watch this session presented by Jeffrey Popma, David Kandzari, Felix Mahfoud and Andrew Sharp in order to understand the latest data on the safety and efficacy of radiofrequency renal denervation including future studies, to learn about the long-term durability of renal denervation in a real-world patient population, and...
Current status of renal denervation techniques for the treatment of hypertension (Part 1)
19 May 2021 – From EuroPCR 2021
Watch this session if you want to review the up-to-date indications, device selection and procedural techniques for renal denervation.
This session was originally presented during EuroPCR 2021.
Current status of renal denervation techniques for the treatment of hypertension (Part 2)
19 May 2021 – From EuroPCR 2021
Watch this session if you want to review the up-to-date indications, device selection and procedural techniques for renal denervation.
This session was originally presented during EuroPCR 2021.
Top Interventional Trials presented at ACC.21
07 Jun 2021
Ali Nazmi Calik provides a summary and key take-aways and infographics of 9 major trials of interest to interventional cardiologists presented at ACC.21
Author
Clinical event reductions in high-risk hypertension patients treated with renal denervation
18 May 2021 – From EuroPCR 2021
Watch this session presented by Roland Schmieder in order to learn about the long-term safety and efficacy of renal denervation in high-risk subgroups from the largest renal denervation data set of real-world patients, to understand how clinical event rates could be reduced following renal denervation as compared...
RADIANCE-HTN TRIO: key takeaways and implications for the treatment of hypertension
18 May 2021 – From EuroPCR 2021
Watch this session presented by Andrew Sharp in order to learn about the recent clinical advancements in the renal denervation procedure with the Paradise Ultrasound RDN system, and to hear the expert's perspective on the recently announced results from RADIANCE-HTN TRIO (blinded, sham-controlled, powered to demonstrate BP lowering...
RADIANCE-HTN TRIO: what does this mean for the treatment of hypertension?
18 May 2021 – From EuroPCR 2021
Watch this session presented by Atul Pathak in order to learn about the recent clinical advancements in the renal denervation procedure with the Paradise Ultrasound RDN system, and to hear the expert's perspective on the recently announced results from RADIANCE-HTN TRIO (blinded, sham-controlled, powered to demonstrate BP lowering...
A review of the RADIANCE-HTN global clinical trial programme: a focus on the TRIO cohort
18 May 2021 – From EuroPCR 2021
Watch this session presented by Ajay Kirtane, Melvin David Lobo and Felix Mahfoud in order to review a history of the field and the recent clinical advancements in renal denervation with the Paradise Ultrasound RDN system, to further examine the recently announced results from RADIANCE-HTN TRIO (blinded, sham-controlled, powered...
Evidence counts: latest Renal Denervation data and the Onyx ONE month DAPT program
19 Oct 2020
On this page you will find a selection of interviews regarding the latest data on renal denervation from TCT Connect 2020, as well as the latest complex sub-analyses from the Onyx ONE Month DAPT program. View a series of short interviews here below!
